HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,450.00
-160.00 (-3.47%)
Aug 5, 2025, 3:30 PM KST
-3.47%
Market Cap542.22B
Revenue (ttm)105.82B
Net Income (ttm)-196.10B
Shares Out121.85M
EPS (ttm)-1,674.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume522,816
Average Volume887,458
Open4,580.00
Previous Close4,610.00
Day's Range4,440.00 - 4,630.00
52-Week Range4,250.00 - 12,520.00
Beta-0.30
RSI34.87
Earnings DateAug 14, 2025

About Lumos Pharma

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.